DePasquale Nicole, Green Jamie A, Ephraim Patti L, Morton Sarah, Peskoe Sarah B, Davenport Clemontina A, Mohottige Dinushika, McElroy Lisa, Strigo Tara S, Hill-Briggs Felicia, Browne Teri, Wilson Jonathan, Lewis-Boyer LaPricia, Cabacungan Ashley N, Boulware L Ebony
Division of General Internal Medicine, Duke University School of Medicine, Durham, NC.
Department of Nephrology, Geisinger Commonwealth School of Medicine, Danville, PA.
Kidney Med. 2022 Aug 4;4(9):100521. doi: 10.1016/j.xkme.2022.100521. eCollection 2022 Sep.
RATIONALE & OBJECTIVE: Choosing from multiple kidney failure treatment modalities can create decisional conflict, but little is known about this experience before decision implementation. We explored decisional conflict about treatment for kidney failure and its associated patient characteristics in the context of advanced chronic kidney disease (CKD).
Cross-sectional study.
SETTING & PARTICIPANTS: Adults (N = 427) who had advanced CKD, received nephrology care in Pennsylvania-based clinics, and had no history of dialysis or transplantation.
Participants' sociodemographic, physical health, nephrology care/knowledge, and psychosocial characteristics.
Participants' results on the Sure of myself; Understand information; Risk-benefit ratio; Encouragement (SURE) screening test for decisional conflict (no decisional conflict vs decisional conflict).
We used multivariable logistic regression to quantify associations between aforementioned participant characteristics and decisional conflict. We repeated analyses among a subgroup of participants at highest risk of kidney failure within 2 years.
Most (76%) participants reported treatment-related decisional conflict. Participant characteristics associated with lower odds of decisional conflict included complete satisfaction with patient-kidney team treatment discussions (OR, 0.16; 95% CI, 0.03-0.88; = 0.04), attendance of treatment education classes (OR, 0.38; 95% CI, 0.16-0.90; = 0.03), and greater treatment-related decision self-efficacy (OR, 0.97; 95% CI, 0.94-0.99; < 0.01). Sensitivity analyses showed a similarly high prevalence of decisional conflict (73%) and again demonstrated associations of class attendance (OR, 0.26; 95% CI, 0.07-0.96; = 0.04) and decision self-efficacy (OR, 0.95; 95% CI, 0.91-0.99; = 0.03) with decisional conflict.
Single-health system study.
Decisional conflict was highly prevalent regardless of CKD progression risk. Findings suggest efforts to reduce decisional conflict should focus on minimizing the mismatch between clinical practice guidelines and patient-reported engagement in treatment preparation, facilitating patient-kidney team treatment discussions, and developing treatment education programs and decision support interventions that incorporate decision self-efficacy-enhancing strategies.
从多种肾衰竭治疗方式中进行选择可能会产生决策冲突,但在决策实施之前,人们对这种体验知之甚少。我们在晚期慢性肾脏病(CKD)的背景下,探讨了肾衰竭治疗的决策冲突及其相关的患者特征。
横断面研究。
患有晚期CKD、在宾夕法尼亚州诊所接受肾脏病护理且无透析或移植史的成年人(N = 427)。
参与者的社会人口统计学、身体健康、肾脏病护理/知识以及心理社会特征。
参与者在“自信;理解信息;风险效益比;鼓励”(SURE)决策冲突筛查测试中的结果(无决策冲突与决策冲突)。
我们使用多变量逻辑回归来量化上述参与者特征与决策冲突之间的关联。我们在2年内肾衰竭风险最高的参与者亚组中重复进行了分析。
大多数(76%)参与者报告了与治疗相关的决策冲突。与决策冲突几率较低相关的参与者特征包括对医患团队治疗讨论完全满意(OR,0.16;95%CI,0.03 - 0.88;P = 0.04)、参加治疗教育课程(OR,0.38;95%CI,0.16 - 0.90;P = 0.03)以及更高的与治疗相关的决策自我效能感(OR,0.97;95%CI,0.94 - 0.99;P < 0.01)。敏感性分析显示决策冲突的患病率同样很高(73%),并再次证明参加课程(OR,0.26;95%CI,0.07 - 0.96;P = 0.04)和决策自我效能感(OR,0.95;95%CI,0.91 - ;P = 0.03)与决策冲突之间的关联。
单医疗系统研究。
无论CKD进展风险如何,决策冲突都非常普遍。研究结果表明,减少决策冲突的努力应集中在尽量减少临床实践指南与患者报告的治疗准备参与度之间的不匹配、促进医患团队治疗讨论,以及制定纳入增强决策自我效能策略的治疗教育计划和决策支持干预措施。